Thromboembolism and anticoagulant therapy during the COVID‑19 pandemic: interim clinical guidance from the anticoagulation forum

Coronavirus disease 2019 (COVID-19) is a viral infection that can, in severe cases, result in cytokine storm, systemic inflammatory response and coagulopathy that is prognostic of poor outcomes. While some, but not all, laboratory findings appear similar to sepsis-associated disseminated intravascular coagulopathy (DIC), COVID-19- induced coagulopathy (CIC) appears to be more prothrombotic than hemorrhagic.

Thromboembolism and anticoagulant therapy during the COVID‑19 pandemic: interim clinical guidance from the anticoagulation forum
Size: 500 KB